超声引导下平阳霉素联合聚桂醇硬化治疗94例囊性淋巴管畸形的疗效

doi:10.6040/j.issn.1671-7554.0.2022.0535

摘要/Abstract

摘要： 目的回顾性分析超声引导下平阳霉素联合聚桂醇经皮硬化治疗囊性淋巴管畸形(cLM)的疗效和安全性。方法共纳入cLM患者94例,年龄0.5~43岁,儿童患者86例,发病时间在2岁之前75例,巨囊型32例、微囊型31例、混合型31例。结果治疗后随访时间3.7~39.2个月,平均治疗次数2.8次,病灶体积减小的有效率为78.7%,症状缓解的有效率为82.1%,患者及家属的满意率为85.1%,14例患者出现不良反应,未出现肺纤维化、过敏等严重不良反应,7例复发患者再次给予治疗,效果好。结论超声引导下平阳霉素联合聚桂醇经皮硬化治疗cLM是一种安全有效的方式,值得临床推广。

关键词: 囊性淋巴管畸形, 淋巴管畸形, 平阳霉素, 聚桂醇, 硬化治疗

Abstract: Objective To retrospectively analyze the efficacy and safety of ultrasound-guided percutaneous sclerotherapy with pingyangmycin and lauromacrogol in the treatment of cystic lymphatic malformation(cLM). Methods A total of 94 cLM patients aged 0.5-43 years were enrolled, 75 of whom had onset before 2 years of age(32 cases of macrocystic type, 31 cases of microcystic type, and 31 cases of mixed type). Results The patients received an average of 2.8 times of treatments. During the follow-up of 3.7-39.2 months, the lesion volume reduction was 78.7%, the effective rate of symptom relief was 82.1%, and the satisfaction rate of patients and their families was 85.1%. Side effects occurred in 14 patients, but no serious adverse reactions such as pulmonary fibrosis or allergies were observed. Recurrence occurred in 7 patients, who received a second treatment and had good outcomes. Conclusion Ultrasound-guided percutaneous sclerotherapy with pingyangmycin and lauromacrogol is effective and safe in the treatment of cystic lymphatic malformation, and it is worthy of clinical promotion.

Key words: Cystic lymphatic malformation, Lymphatic malformation, Pingyangmycin, Lauromacrogol, Sclerotherapy

中图分类号:

R622

王文静,刘博策,毕见海,霍然. 超声引导下平阳霉素联合聚桂醇硬化治疗94例囊性淋巴管畸形的疗效[J]. 山东大学学报 (医学版), 2022, 60(8): 72-78.

WANG Wenjing, LIU Boce, BI Jianhai, HUO Ran. Efficacy of ultrasound-guided sclerotherapy with pingyangmycin and lauromacrogol in 94 cases of cystic lymphatic malformation[J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 72-78.

参考文献

[1] 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J].组织工程与重建外科杂志, 2019, 15(5): 277-317.
[2] Kulungowski AM, Patel M. Lymphatic malformations [J]. Semin Pediatr Surg, 2020, 29(5): 150971.
[3] Mäkinen T, Boon LM, Vikkula M, et al. Lymphatic malformations: genetics, mechanisms and therapeutic strategies [J]. Circ Res, 2021, 129(1): 136-154.
[4] Perkins JA, Manning SC, Tempero RM, et al. Lymphatic malformations: current cell ularand clinica linvestigations [J]. Otolaryngol Head Neck Surg, 2010, 142(6): 789-794.
[5] McCuaig CC. Update on classification and diagnosis of vascular malformations. [J]. Curr Opin Pediatr, 2017, 29(4): 448-454.
[6] Janardhan HP, Saheera S, Jung R, et al. Vascular and lymphatic malformations: perspectives from human and vertebrate studies [J]. Circ Res, 2021, 129(1): 131-135.
[7] De Leacy R, Bageac DV, Manna S, et al. A radiologic grading system for assessing the radiographic outcome of treatment in lymphatic and lymphatic-venous malformations of the head and neck [J]. AJNR Am J Neuroradiol, 2021, 42(10): 1859-1864.
[8] Berenstein A, Bazil MJ, Sorscher M, et al. Percutaneous sclerotherapy of microcystic lymphatic malformations: the use of an innovative gravity-dependent technique [J]. J Neurointerv Surg, 2022, 28: 018526. doi: 10.1136/neurintsurg-2021-018526.
[9] Elluru RG, Balakrishnan K, Padua HM. Lymphatic malformations: diagnosis andmanagement [J]. Semin Pediatr Surg,2014,23(4): 178-185.
[10] Cursiefen C, Chen L, Dana MR, et al. Corneal lymphangiogenesis: evidence, mechanism, and implications for corneal transplant immunology [J]. Cornea, 2003, 22(3): 273-281.
[11] Liersch R, Detmar M. Lymphangiogenesis in development and disease [J]. Thromb Haemost, 2007, 98(2): 304-310.
[12] Bekisz S, Baudin L, Buntinx F, et al. In vitro, in vivo, and in silico models of lymphangiogenesis in solid malignancies [J]. Cancers(Basel), 2022,14(6):1525.
[13] Oliver G. Lymphatic vasculature development [J]. Nat Rev Immunol, 2004,4(1): 35-45.
[14] Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA [J]. J Pediatr,2015,166:1048-1054. doi: 10.1016/j.jpeds.2014.12.069.
[15] Zenner K, Jensen DM, Dmyterko V, et al. Somatic activating BRAF variants. cause isolated lymphatic malformations [J]. HGG Adv,2022,3(2):100101.
[16] Martinez-Corral I, Zhang Y, Petkova M, et al. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation [J]. Nat Commun,2020,11(1):2869.
[17] Kato M, Watanabe S, Iida T, et al. Flow pattern classification in lymphatic malformations by indocyanine green lymphography [J]. Plast Reconstr Surg, 2019,143(3):558e-564e.
[18] Bhatnagar A, Neyaz Z, Singh B, et al. Bleomycin sclerotherapy in massive macrocystic lymphatic malformation: minimal complications with maximum results [J]. J Cutan Aesthet Surg, 2020,13(4):319-325.
[19] 谢义民,陈强,王玲,等. 聚桂醇瘤腔内注射治疗小儿囊性淋巴管瘤[J].中华小儿外科杂志,2017,38(9):704-707. XIE Yimin, CHEN Qiang, WANG Ling, et al. Intratumoral injection of lauromacrogol for children with cyctic lymphangioma [J]. Chinese Journal of Pediatric Surgery,2017,38(9):704-707.
[20] Fuentes S, Delgado D, Marti E, et al. Treatment of lymphatic malformations with OK-432 sclerosis: our experience [J]. Cir Pediatr,2010,23(2):88-91.
[21] Horbach SE, Lokhorst MM, Saeed P, et al. Sclerotherapy for low-flow vascular malformations of the head and neck: a systematic review of sclerosing agents [J]. J Plast Reconstr Aesthetic Surg, 2016, 69:295-304. doi: 10.1016/j.bjps.2015.10.045.
[22] Fernandes S, Yeung P, Heran M, et al. Sclerosing agents in the management of lymphatic malformations in children: a systematic review [J]. J Pediatr Surg, 2022, 57(5):888-896.
[23] Al-Faky YH, Alkatan HM. Histopathological changes of lymphatic malformation after bleomycin injection [J]. Arq Bras Oftalmol, 2022, 21:s0004. doi: 10.5935/0004-2749.20230048.
[24] Cho AL, Kiang SC, Lodenkamp J, et al. Fatal lung toxicity after intralesionalbleomycin sclerotherapy of a vascular malformation [J]. Cardiovasc Intervent Radiol,2020,43(4):648-651.
[25] Blaise S, Charavin-Cocuzza M, Riom H, et al. Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review [J]. Eur J Vasc Endovasc Surg, 2011,41(3):412-417.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32 -37 .
[2]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7 -14 .
[3]	付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24 -31 .
[4]	索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1 -6 .
[5]	龙婷婷,谢明,周璐,朱俊德. Noggin蛋白对小鼠脑缺血再灌注损伤后学习和记忆能力与齿状回结构的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 15 -23 .
[6]	李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38 -46 .
[7]	丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60 -66 .
[8]	肖娟,肖强,丛伟,李婷,丁守銮,张媛,邵纯纯,吴梅,刘佳宁,贾红英. 两种甲状腺超声数据报告系统诊断效能的比较[J]. 山东大学学报 (医学版), 2020, 1(7): 53 -59 .
[9]	史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47 -52 .
[10]	郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72 -76 .